CoRISMA MCS Systems — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

CoRISMA MCS Systems, founded in 2010 and headquartered in San Diego, is a private medical device company advancing a novel non-invasive monitoring platform for cardiovascular care. The company's flagship CoRISMA MCS system uses multi-channel signal processing to provide continuous, real-time data on cardiac output and other hemodynamic parameters, targeting the significant unmet need in managing conditions like cardiogenic shock. While likely pre-revenue or in early revenue stages, CoRISMA is positioning its technology as a potential alternative to more invasive pulmonary artery catheters, aiming to improve patient outcomes and reduce healthcare costs in critical care and surgery. The company appears to be in a commercial or late-stage development phase for its core system, seeking adoption in hospital settings.

Cardiovascular

Technology Platform

Non-invasive, multi-channel signal processing system for continuous, real-time hemodynamic monitoring (e.g., cardiac output).

Opportunities

The large and growing hemodynamic monitoring market, driven by aging populations and complex surgeries, presents a significant opportunity.

CoRISMA's non-invasive technology can capture share from risky invasive methods and compete with other non-invasive devices by offering continuous, actionable data to guide critical care decisions.

The shift towards value-based healthcare creates demand for tools that improve outcomes and reduce complications.

Risk Factors

Key risks include slow commercial adoption against entrenched competitors, the need for continuous clinical validation to prove superior outcomes, and the financial pressures of being a private company scaling in a capital-intensive market.

Technological obsolescence and intellectual property challenges are also persistent threats.

Competitive Landscape

CoRISMA competes in the hemodynamic monitoring space against invasive pulmonary artery catheters, minimally invasive pulse contour analysis devices (e.g., Edwards Lifesciences), and other non-invasive technologies like bioreactance (e.g., Cheetah Medical). Its differentiation hinges on providing continuous, comprehensive data non-invasively, aiming to offer a safer and more practical alternative for guiding fluid and drug therapy in unstable patients.

More companies in United States →